SanBio Co. Ltd. | Cash Flow

Fiscal year is February-January. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
589
2,228
1,172
2,166
3,939
2,919
Depreciation, Depletion & Amortization
4
6
14
27
54
37
Other Funds
-
1
6
381
1,381
747
Funds from Operations
583
2,238
1,164
1,759
2,504
3,630
Changes in Working Capital
471
2,457
198
68
534
398
Net Operating Cash Flow
112
219
1,362
1,827
1,970
4,027
Capital Expenditures
10
3
60
97
32
Sale of Fixed Assets & Businesses
-
-
-
3
-
Purchase/Sale of Investments
536
473
370
175
697
Net Investing Cash Flow
523
480
436
79
658
Issuance/Reduction of Debt, Net
-
1,200
-
100
1,000
Net Financing Cash Flow
-
1,374
7,402
190
1,046
Net Change in Cash
402
790
5,659
2,011
222
Free Cash Flow
122
222
1,422
1,924
2,003
Change in Capital Stock
-
173
7,402
90
46
Exchange Rate Effect
10
115
55
454
44
Other Uses
3
4
6
1
7
Miscellaneous Funds
-
-
-
-
-

About SanBio Co.

View Profile
Address
St. Luke Tower, 28/F
Tokyo Tokyo 104
Japan
Employees -
Website http://www.sanbio.jp
Updated 07/08/2019
SanBio Co., Ltd. engages in the development and sale of regenerative cells pharmaceuticals. It also provides regenerative therapies for neurological disorders that include stroke, traumatic brain injury, eye diseases, and Parkinson's disease. The company was founded by Keita Mori and Toru Kawanishi in February 2001 and is headquartered in Tokyo, Japan.